Skip to main content
. 2014 Aug 8;4:6000. doi: 10.1038/srep06000

Figure 5. Mutation in the MZF1-binding site attenuated activation of the DR5 promoter due to sulindac sulfide.

Figure 5

(a) The sulindac sulfide-responsive region in the DR5 promoter and MZF1-binding sequences are shown. The predicted transcription factor-binding sites are shown using TFSEARCH 1.3. Mutation sequences are described in small letters. (b) The luciferase assay was performed as described in Figure 3 with the indicated reporter plasmids. Data represent the means of triplicate experiments (bars, S.D.). +: treated with 200 μM sulindac sulfide for 24 h, −: treated with solvent DMSO. *: p < 0.05 (c) Nuclear extract from cells treated with sulindac sulfide or DMSO were analyzed by gel shift assay, as described in Materials and methods. Increased amounts of the unlabeled oligonucleotides (×2 or ×8) were used as competitors. WT: wild-type MZF1-binding site of DR5 promoter. MT: mutant MZF1-binding site of DR5 promoter.